Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Bigfoot Biomedical Gets $45 Million of Financing Led by Abbott Labs

share with twitter share with LinkedIn share with facebook
share via e-mail
01/13/2020 | 04:17pm EST

By Josh Beckerman

Abbott Laboratories (ABT) led $45 million of financing for Bigfoot Biomedical, the initial tranche of a Series C round.

The funding also included Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management.

Bigfoot is developing the Bigfoot Unity Diabetes Management Program, an insulin dosing platform that integrates Abbott's FreeStyle Libre glucose sensing technology.

Write to Josh Beckerman at josh.beckerman@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 1.11% 89.66 Delayed Quote.3.22%
JANUS HENDERSON GROUP PLC -3.03% 25.26 Delayed Quote.3.31%
SENVEST CAPITAL INC. -1.16% 171 Delayed Quote.0.91%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBOTT LABORATORIES
02/11ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
02/05WALL STREET STOCK EXCHANGE : Tiffany is part of LVMH, Tesla gives some bad news,..
02/04ABBOTT LABORATORIES : Gets FDA Breakthrough Designation for Fully Implantable He..
DJ
02/04ABBOTT : 's In-Development Fully Implantable Heart Pump System Earns FDA's Break..
PR
02/03ABBOTT : Announces First-of-Its-Kind Trial to Assess New Therapy Option for Peop..
PR
01/31ABBOTT LABORATORIES : Tendyne device receives world's first ce mark for transcat..
AQ
01/30ABBOTT : 's Tendyne™ Device Receives World's First CE Mark for Transcathet..
PR
01/27ABBOTT LABORATORIES : Receives expanded indication from the u.s. fda for directi..
AQ
01/24Abbott Laboratories Gets Expanded Indication for Infinity Deep Brain Stimulat..
DJ
01/24ABBOTT : Receives Expanded Indication From the U.S. FDA for Directional Deep Bra..
PR
More news
Financials (USD)
Sales 2020 34 120 M
EBIT 2020 7 754 M
Net income 2020 4 460 M
Debt 2020 10 170 M
Yield 2020 1,56%
P/E ratio 2020 35,5x
P/E ratio 2021 28,9x
EV / Sales2020 4,95x
EV / Sales2021 4,49x
Capitalization 159 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 99,28  $
Last Close Price 89,66  $
Spread / Highest target 22,7%
Spread / Average Target 10,7%
Spread / Lowest Target -13,0%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President & Chief Operating Officer
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES3.22%158 560
MASIMO CORPORATION16.14%9 841
NOVOCURE LIMITED10.55%9 220
ASAHI INTECC CO., LTD.-1.27%7 389
PENUMBRA, INC.15.93%6 649
GETINGE-2.93%4 816